Pediatric Soft Tissue Sarcomas

Surgical Clinics of North America

Volumn 88, Issue 3, 2008, Pages 615-627

  Loeb, David M ^a   Thornton, Katherine ^a,b   Shokek, Ori ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FAMILIAL CANCER; HUMAN; NEUROFIBROMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SEX DIFFERENCE; SOFT TISSUE SARCOMA;

CHILD; HUMANS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA, EMBRYONAL; SOFT TISSUE NEOPLASMS;

EID: 44449105496     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.03.008     Document Type: Review

References (35)

1. Gurney J., Young Jr. J.L., Roffers S.D., et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Vol NIH Pub. 99-4649 (1999), National Cancer Institute; SEER Program, Bethesda (MD)
2. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 4985 (1990) 1233-1238
3. Pizzo P.A., and Poplack D.G. Principles and practice of pediatric oncology. 4th edition (2002), Lippincott Williams & Wilkins, Philadelphia
4. Yang P., Grufferman S., Khoury M.J., et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol 12 5 (1995) 467-474
5. McDowell H.P. Update on childhood rhabdomyosarcoma. Arch Dis Child 88 4 (2003) 354-357
6. Seale P., Sabourin L.A., Girgis-Gabardo A., et al. Pax7 is required for the specification of myogenic satellite cells. Cell 102 6 (2000) 777-786
7. Lam P.Y., Sublett J.E., Hollenbach A.D., et al. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19 1 (1999) 594-601
8. Klem M.L., Grewal R.K., Wexler L.H., et al. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 29 1 (2007) 9-14
9. Meza J.L., Anderson J., Pappo A.S., et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 24 24 (2006) 3844-3851
10. Neville H.L., Andrassy R.J., Lobe T.E., et al. Preoperative staging, prognostic factors, and outcome for extremity rhabdomyosarcoma: a preliminary report from the Intergroup Rhabdomyosarcoma Study IV (1991-1997). J Pediatr Surg 35 2 (2000) 317-321
11. McMulkin H.M., Yanchar N.L., Fernandez C.V., et al. Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int 19 6 (2003) 453-456
12. Godbule P., Outram A., Wilcox D.T., et al. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications. J Urol 176 (2006) 1751-1754
13. Wolden S.L., Anderson J.R., Crist W.M., et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol 17 11 (1999) 3468-3475
14. Smith L.M., Anderson J.R., Qualman S.J., et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 19 20 (2001) 4058-4064
15. Donaldson S.S., Meza J., Breneman J.C., et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. Int J Radiat Oncol Biol Phys 51 3 (2001) 718-728
16. Donaldson S.S., and Anderson J.R. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol 23 12 (2005) 2586-2587
17. Stevens M.C., Rey A., Bouvet N., et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23 12 (2005) 2618-2628
18. McArthur G.A., Demetri G.D., van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23 4 (2005) 866-873
19. Peng F., Rabkin G., and Muzik O. Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin Nucl Med 31 7 (2006) 394-397
20. Volker T., Denecke T., Steffen I., et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25 34 (2007) 5435-5441
21. Ball A.B., Fisher C., Pittam M., et al. Diagnosis of soft tissue tumours by Tru-Cut biopsy. Br J Surg 77 7 (1990) 756-758
22. Barth Jr. R.J., Merino M.J., Solomon D., et al. A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. Surgery 112 3 (1992) 536-543
23. Heslin M.J., Lewis J.J., Woodruff J.M., et al. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 4 5 (1997) 425-431
24. Clark M.A., Fisher C., Judson I., et al. Soft-tissue sarcomas in adults. N Engl J Med 353 7 (2005) 701-711
25. Clark M.A., and Thomas J.M. Amputation for soft-tissue sarcoma. Lancet Oncol 4 6 (2003) 335-342
26. Spiro I.J., Rosenberg A.E., Springfield D., et al. Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience. Cancer Invest 13 1 (1995) 86-95
27. Kattan M.W., Leung D.H., and Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20 3 (2002) 791-796
28. Eilber F.C., Brennan M.F., Eilber F.R., et al. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer 101 10 (2004) 2270-2275
29. Ferrari A., Miceli R., Casanova M., et al. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. Eur J Cancer 43 18 (2007) 2691-2697
30. Spunt S.L., Hill D.A., Motosue A.M., et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol 20 15 (2002) 3225-3235
31. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 7 (1993) 1269-1275
32. Verweij J., van Oosterom A.T., Somers R., et al. Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. Ann Oncol 3 Suppl 2 (1992) S75-S80
33. O'Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359 9325 (2002) 2235-2241
34. Davis A.M., O'Sullivan B., Bell R.S., et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 20 22 (2002) 4472-4477
35. Davis A.M., O'Sullivan B., Turcotte R., et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 75 1 (2005) 48-53